Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 611

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1C
Chunk 611
---
.9 million of cash, resulting from $1.7 million in net borrowings from
a related party, $1.5 million in net borrowings under a related party line of credit, $1.0 million from the sale of common stock and
offset by a $0.3 million in deferred offering cost and $0.05 million in repayments to a related party.

To
date, we have not generated any revenue from product sales. We do not expect to generate revenue from product sales unless and until
we successfully complete pre-clinical and clinical development of, receive regulatory approval for, and commercialize a program and we
do not know when, or if at all, that will occur. We expect our expenses to increase substantially in connection with our ongoing activities,
particularly as we advance the pre-clinical activities and studies and initiate clinical trials. In addition, if we obtain regulatory
approval for any programs, we expect to incur significant expenses related to product sales, marketing, and distribution to the extent
that such sales, marketing and distribution are not the responsibility of potential collaborators. The timing and amount of our operating
expenditure will depend largely on the factors set out above.

51

Our
funding requirements and timing and amount of our operating expenditure will depend on many factors, including, but not limited to:

    ●
    the
    rate of progress in the development of our Telomir-1 program and other development programs;

    ●
    the
    scope, progress, results and costs of pre-clinical studies and clinical trials for any other current and future programs;

    ●
    the
    number and characteristics of programs and technologies that we develop or may in-license;

    ●
    the
    costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our
    programs for which we receive marketing approval;

    ●
    the
    costs necessary to obtain regulatory approvals, if any, for any approved products in the United States and other jurisdictions, and
    the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained;

    ●
    the
    costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights
    and defending any intellectual property-related claims;

    ●
    the
    continuation of our existing licensing arrangements and entry into new collaborations and licensing